Regulation of calcium currents and secretion by magnesium in crustacean peptidergic neurons

Dopaminergic regulation of crustacean hyperglycemic hormone and glucose levels in the hemolymph of the crayfish Procambarus clarkii

The effects of dopamine on crustacean hyperglycemic hormone (CHH) release and hemolymph glucose levels in the crayfish Procambarus clarkii were investigated. A quantitative sandwich enzyme-linked immunosorbent assay (ELISA) using antibodies specific for Prc CHH was developed and characterized. The sensitivity of the ELISA was about 1 fmol/well. Specific measurement of CHH in hemolymph samples by the ELISA was demonstrated by the parallelism between CHH standard curve and sample (hemolymph) titration curve. Moreover, thermally stressed P. clarkii exhibited a characteristic change of hemolymph CHH levels as revealed by the ELISA. CHH and glucose levels increased significantly within 30 min of dopamine injection, peaked at 1 h, and returned to the basal levels at 4 h. Dose-dependent effects of dopamine on CHH and glucose levels were observed between 10(-8) to 10(-6) mol/animal. Dopamine-induced increases in CHH and glucose levels were absent in eyestalk-ablated animals. Finally, dopamine significantly stimulated the release of CHH from in vitro incubated eyestalk ganglia. These results suggest that dopamine enhances release of CHH into hemolymph that in turn evokes hyperglycemic responses and that the predominant site of dopamine-induced CHH release is the X-organ-sinus gland complex located within the eyestalk.

Serotonergic regulation of crustacean hyperglycemic hormone secretion in the crayfish, Procambarus clarkii

These studies investigate if crustacean hyperglycemic hormone (CHH) is involved in 5-hydroxytryptamine (5-HT)-induced hyperglycemia. Eyestalk ganglia with intact X-organ-sinus gland complex were dissected from the crayfish Procambarus clarkii and incubated under various experimental conditions. Incubation media were then analyzed for the presence of released hyperglycemic factor using an in vivo bioassay. The results show that 5-HT enhanced release of hyperglycemic factor in a dose-dependent manner. This stimulatory effect of 5-HT was significantly decreased by adding ketanserin or methysergide (both 5-HT receptor antagonists) into incubation of eyestalk ganglia. Further, activity of the 5-HT-released hyperglycemic factor could be eliminated by adsorption of incubation media with anti-CHH serum but not by preimmune or anti-5-HT serum. These results confirm the hypothesis that 5-HT enhances release of CHH, which in turn elicits hyperglycemic responses. It is probable that 5-HT activates an excitation-secretion coupling mechanism by interacting with receptors located on the X-organ neurosecretory cells.